NCT04733417 2023-04-13A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.Tianjin Medical University Cancer Institute and HospitalPhase 2 Unknown35 enrolled
NCT04129996 2022-01-11A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)Fudan UniversityPhase 2 Unknown46 enrolled